Donald School Journal of Ultrasound in Obstetrics and Gynecology

Register      Login

VOLUME 12 , ISSUE 2 ( April-June, 2018 ) > List of Articles

ORIGINAL ARTICLE

Evaluation of the Four-dimensional “Spatiotemporal Image Correlation” Technology with High-definition Color Doppler as Third Step for Preoperative Differential Diagnosis of Ovarian Tumors: A Prospective Study

Alvaro Ruiz-Zambrana, María Aubá, Begoña Olartecoechea, Matías Jurado, Stefano Guerriero, Juan L Alcázar, Tania Errasti, José Á Minguez

Keywords : Adnexal masses, Power Doppler, Spatiotemporal image correlation, Two-dimensional, Ultrasound

Citation Information : Ruiz-Zambrana A, Aubá M, Olartecoechea B, Jurado M, Guerriero S, Alcázar JL, Errasti T, Minguez JÁ. Evaluation of the Four-dimensional “Spatiotemporal Image Correlation” Technology with High-definition Color Doppler as Third Step for Preoperative Differential Diagnosis of Ovarian Tumors: A Prospective Study. Donald School J Ultrasound Obstet Gynecol 2018; 12 (2):108-115.

DOI: 10.5005/jp-journals-10009-1560

License: CC BY-NC 4.0

Published Online: 01-04-2018

Copyright Statement:  Copyright © 2018; The Author(s).


Abstract

Aim: The purpose of this study is to analyze whether the addition of volumetric pulsatility indices (vPI) derived from spatiotemporal image correlation (STIC) assessment could improve the diagnostic performance of conventional two-dimensional (2D) ultrasound for discriminating benign from malignant adnexal tumors used as a third sequential step. Study design: Ours was an observational prospective cohort study between September 2014 to September 2016. Women diagnosed as having a persistent ovarian tumor evaluated at our center were included in this study. All women underwent transvaginal ultrasonography before surgery to assess the ultrasonographic characteristics of the lesion by gray-scale morphological analysis classifying the lesion as benign or suspicious based on “pattern recognition”. In benign lesions, no further test was conducted. For those tumors regarded as suspicious, assessment of the vascularization was performed by using conventional 2D high-definition flow color Doppler (2D-HDF), classifying the lesion as suspicious if vascularization within solid component was detected. In those lesions with intratumoral vascularization, four-dimensional (4D)-STIC technology with HDF was applied for calculating vPI. We used two reference standards: Definitive histology when the mass was surgically removed and in case the mass was not removed, those with spontaneous resolution or persistent without change and follow-up longer than 12 months were considered as benign. We compared diagnostic performance of conventional approach (pattern recognition followed by 2D-HDF) vs pattern recognition followed by 2D-HDF followed by 4D-STIC. Results: A total of 214 patients were included; 175 had a benign tumor and 39 a malignant tumor. We observed that vPI was significantly lower in malignant masses as compared with benign masses when 4D-STIC was used. Sensitivity and specificity of B-mode + 2D-HDF were 0.95 [95% confidence interval (CI): 0.83–0.98] and 0.92 (95% CI: 0.87–0.95) respectively. Sensitivity and specificity of B-mode + 2D-HDF + 4D-STIC were 0.95 (95% CI: 0.83–0.98) and 0.94 (95% CI: 0.90–0.96)respectively. No significant differences by adding the STIC were observed (McNemar test p > 0.05). Conclusion: The 4D-STIC does not improve the diagnostic performance of conventional ultrasound in the differential diagnosis of ovarian tumors as compared with conventional assessment using 2D ultrasound. However, a low vPI increases significantly the probability of malignancy in questionable masses.


PDF Share
  1. Timmerman D, Schwärzler P, Collins WP, Claerhout F, Coenen M, Amant F, Vergote I, Bourne TH. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 1999 Jan;13(1):11-16.
  2. Sokalska A, Timmerman D, Testa AC, Van Holsbeke C, Lissoni AA, Leone FP, Jurkovic D, Valentin L. Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses. Ultrasound Obstet Gynecol 2009 Oct;34(4):462-470.
  3. Alcázar JL, Guerriero S, Laparte C, Ajossa S, Ruiz-Zambrana A, Melis GB. Diagnostic performance of transvaginal grayscale ultrasound for specific diagnosis of benign ovarian cysts in relation to menopausal status. Maturitas 2011 Feb;68(2):182-198.
  4. Brown DL, Dudiak KM, Laing FC. Adnexal masses: US characterization and reporting. Radiology 2010 Feb;254(2): 342-354.
  5. Alcázar JL, Guerriero S, Laparte C, Ajossa S, Jurado M. Contribution of power Doppler blood flow mapping to grayscale ultrasound for predicting malignancy of adnexal masses in symptomatic and asymptomatic women. Eur J Obstet Gynecol Reprod Biol 2011 Mar;155(1):99-105.
  6. Alcázar JL, Utrilla-Layna J, Mínguez JÁ, Jurado M. Clinical and ultrasound features of type I and type II epithelial ovarian cancer. Int J Gynecol Cancer 2013 May;23(4):680-684.
  7. Guerriero S, Alcazar JL, Ajossa S, Galvan R, Laparte C, García- Manero M, Lopez-Garcia G, Melis GB. Transvaginal color Doppler imaging in the detection of ovarian cancer in a large study population. Int J Gynecol Cancer 2010 Jul;20(5):781-786.
  8. Alcázar JL, Errasti T, Mínguez JA, Galán MJ, García-Manero M, Ceamanos C. Sonographic features of ovarian cystadenofibromas: spectrum of findings. J Ultrasound Med 2001 Aug;20(8):915-919.
  9. Van Holsbeke C, Daemen A, Yazbek J, Holland TK, Bourne T, Mesens T, Lannoo L, Boes AS, Joos A, Van De Vijver A, et al. Ultrasound experience substantially impacts on diagnostic performance and confidence when adnexal masses are classified using pattern recognition. Gynecol Obstet Invest 2010;69(3):160-168.
  10. Valentin L, Ameye L, Savelli L, Fruscio R, Leone FP, Czekierdowski A, Lissoni AA, Fischerova D, Guerriero S, Van Holsbeke C, et al. Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can classify them reliably as benign or malignant before surgery? Ultrasound Obstet Gynecol 2013 May;41(5):570-581.
  11. Juez L, Peces AR, Martinez-Astorquiza Corral T, Alcazar JL. Ultrasound features for determining the risk of malignancy in unilocular-solid adnexal masses in premenopausal women without ascites and/or carcinomatosis. Donald School J Ultrasound Obstet Gynecol 2015 Sep;9(S1):112-117.
  12. Alcázar JL, Royo P, Jurado M, Mínguez JA, García-Manero M, Laparte C, Galván R, López-García G. Triage for surgical management of ovarian tumors in asymptomatic women: assessment of an ultrasound-based scoring system. Ultrasound Obstet Gynecol 2008 Aug;32(2):220-225.
  13. Kurjak A, Kupesic S, Anic T, Kosuta D. Three-dimensional ultrasound and power doppler improve the diagnosis of ovarian lesions. Gynecol Oncol. 2000 Jan;76(1):28-32.
  14. Alcázar JL, Mercé LT, García Manero M. Three-dimensional power Doppler vascular sampling: a new method for predicting ovarian cancer in vascularized complex adnexal masses. J Ultrasound Med 2005 May;24(5):689-696.
  15. Geomini PM, Kluivers KB, Moret E, Bremer GL, Kruitwagen RF, Mol BW. Evaluation of adnexal masses with three-dimensional ultrasonography. Obstet Gynecol 2006 Nov;108(5):1167-1175.
  16. Alcázar JL, Rodriguez D. Three-dimensional power Doppler vascular sonographic sampling for predicting ovarian cancer in cystic-solid and solid vascularized masses. J Ultrasound Med 2009 Mar;28(3):275-281.
  17. Ohel I, Sheiner E, Aricha-Tamir B, Piura B, Meirovitz M, Silberstein T, Hershkovitz R. Three-dimensional power Doppler ultrasound in ovarian cancer and its correlation with histology. Arch Gynecol Obstet 2010 May;281(5):919-925.
  18. Perez-Medina T, Orensanz I, Pereira A, Valero de Bernabé J, Engels V, Troyano J, SanFrutos L, Iglesias E. Three-dimensional angioultrasonography for the prediction of malignancy in ovarian masses. Gynecol Obstet Invest 2013;75(2):120-125.
  19. Utrilla-Layna J, Alcázar JL, Aubá M, Laparte C, Olartecoechea B, Errasti T, Juez L, Mínguez JÁ, Guerriero S, Jurado M. Performance of three-dimensional power Doppler angiography as third-step assessment in differential diagnosis of adnexal masses. Ultrasound Obstet Gynecol 2015 May;45(5): 613-617.
  20. Kudla MJ, Alcázar JL. Spatiotemporal image correlation using high-definition flow: a new method for assessing ovarian vascularization. J Ultrasound Med 2010 Oct;29(10):1469-1474.
  21. Martins WP, Welsh AW, Lima JC, Nastri CO, Raine-Fenning NJ. The “volumetric” pulsatility index as evaluated by spatiotemporal imaging correlation (STIC): a preliminary description of a novel technique, its application to the endometrium and an evaluation of its reproducibility. Ultrasound Med Biol 2011 Dec;37(12):2160-2168.
  22. Alcázar JL, Kudla MJ. Ovarian stromal vessels assessed by spatiotemporal image correlation-high definition flow in women with polycystic ovary syndrome: a case-control study. Ultrasound Obstet Gynecol 2012 Oct;40(4):470-475.
  23. Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I, International Ovarian Tumor Analysis (IOTA) Group. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol 2000 Oct;16(5):500-505.
  24. Kudla MJ, Alcázar JL. Spatiotemporal image correlation with spherical sampling and high-definition flow: new 4-dimensional method for assessment of tissue vascularization changes during the cardiac cycle: reproducibility analysis. J Ultrasound Med 2012 Jan;31(1):73-80.
  25. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament (AFIP Atlas of tumor pathology No. 23). Washington, DC: Armed Forces Institute of Pathology; 1998.
  26. Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2012 Oct;119 (Suppl 2): S118-S129.
  27. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007 Oct 20;370(9596):1453-1457.
  28. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract 2004 Feb;21(1): 4-10.
  29. Valentin L, Ameye L, Jurkovic D, Metzger U, Lécuru F, Van Huffel S, Timmerman D. Which extrauterine pelvic masses are difficult to correctly classify as benign or malignant on the basis of ultrasound findings and is there a way of making a correct diagnosis? Ultrasound Obstet Gynecol 2006 Apr;27(4):438-444.
  30. Valentin L, Ameye L, Savelli L, Fruscio R, Leone FP, Czekierdowski A, Lissoni AA, Fischerova D, Guerriero S, Van Holsbeke C, et al. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound Obstet Gynecol 2011 Oct;38(4):456-465.
  31. Valentin L, Jurkovic D, Van Calster B, Testa A, Van Holsbeke C, Bourne T, Vergote I, Van Huffel S, Timmerman D. Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol 2009 Sep;34(3): 345-354.
  32. Anthoulakis C, Nikoloudis N. Pelvic MRI as the “gold standard” in the subsequent evaluation of ultrasound-indeterminate adnexal lesions: a systematic review. Gynecol Oncol 2014 Mar;132(3):661-668.
  33. Kudla M, Alcazar JL. 3DPD imaging of ovarian pathology: advantages and limitation of the method. How can we standardize the results? Donald School J Ultrasound Obstet Gynecol 2009;3:47-53.
  34. Miyague AH, Pavan TZ, Grillo FW, Teixeira DM, Nastri CO, Martins WP. Influence of attenuation on three-dimensional power Doppler indices and STIC volumetric pulsatility index: a flow phantom experiment. Ultrasound Obstet Gynecol 2014 Jan;43(1):103-105.
  35. Alcázar JL, Olartecoechea B, Guerriero S, Jurado M. Expectant management of adnexal masses in selected premenopausal women: a prospective observational study. Ultrasound Obstet Gynecol 2013 May;41(5):582-588.
  36. Glanc P, Benacerraf B, Bourne T, Brown D, Coleman BG, Crum C, Dodge J, Levine D, Pavlik E, Timmerman D, et al. First International Consensus Report on Adnexal Masses: management recommendations. J Ultrasound Med 2017 May;36(5):849-863.
  37. Hata T, AboEllail MA, Sajapala S, Ishimura M, Masaoka H. HDlive Silhouette mode with spatiotemporal image correlation for assessment of the fetal heart. J Ultrasound Med 2016 Jul;35(7):1489-1495.
  38. DeVore GR, Satou G, Sklansky M. 4D fetal echocardiography— an update. Echocardiography 2017 Dec;34(12):1788-1798.
  39. Tedesco GD, de Souza Bezerra M, Barros FS, Martins WP, Nardozza LM, Carrilho MC, Moron AF, Carvalho FH, Rolo LC, Araujo Júnior E. Reference ranges of fetal cardiac biometric parameters using three-dimensional ultrasound with spatiotemporal image correlation M mode and their applicability in congenital heart diseases. Pediatr Cardiol 2017 Feb;38(2):271-279.
  40. Guasina F, Bellussi F, Morganelli G, Salsi G, Pilu G, Simonazzi G. Electronic spatiotemporal image correlation improves fourdimensional fetal echocardiography. Ultrasound Obstet Gynecol 2018 Mar;51(3):357-360.
  41. Merz E, Pashaj S. Current role of 3D/4D sonography in obstetrics and gynecology. Donald School J Ultrasound Obstet Gynecol 2013;7(4):400-408.
  42. Merz E. Transvaginal 3D/4D ultrasound and its application in gynecology. In: Merz E, ed. Ultrasound in obstetrics and gynecology. Vol. 2: Gynecology. New York, Stuttgart: Thieme;2007. pp. 222-240.
  43. Dietz HP. Ultrasound imaging of the pelvic floor. Part II: threedimensional or volume imaging. Ultrasound Obstet Gynecol 2004 Jun;23(6):615-625.
  44. Dietz HP, Moegni F, Shek KL. Diagnosis of levator avulsion injury: a comparison of three methods. Ultrasound Obstet Gynecol 2012;40:693-698.
  45. Moini A, Mohammadi S, Hosseini R, Eslami B, Ahmadi F. Accuracy of 3-dimensional sonography for diagnosis and classification of congenital uterine anomalies. J Ultrasound Med 2013 Jun;32(6):923-927.
  46. Tabi S, Kupesic Plavsic S. The role of three-dimensional ultrasound in the assessment of congenital uterine anomalies. Donald School J Ultrasound Obstet Gynecol 2012;6(4): 415-423.
  47. Jurkovic D, Geipel A, Gruboeck K, Jauniaux E, Natucci M, Campbell S. Three-dimensional ultrasound for the assessment of uterine anatomy and detection of congenital anomalies: a comparison with hysterosalpingography and two-dimensional sonography. Ultrasound Obstet Gynecol 1995 Apr;5(4):233-237.
  48. Mercé LT, Barco MJ, Bau S, Troyano JM. Prediction of ovarian response and IVF/ICSI outcome by three-dimensional ultrasonography and power Doppler angiography. Eur J Obstet Gynecol Reprod Biol 2007 May;132(1):93-100.
  49. Zhang T, He Y, Wang Y, Zhu Q, Yang J, Zhao X, Sun Y. The role of three-dimensional power Doppler ultrasound parameters measured on hCG day in the prediction of pregnancy during in vitro fertilization treatment. Eur J Obstet Gynecol Reprod Biol 2016 Aug;203:66-71.
  50. Maged AM, Ramzy AM, Ghar MA, El Shenoufy H, Gad Allah SH, Wahba AH, ElKateb AY, Hwedi N. 3D ultrasound assessment of endometrial junctional zone anatomy as a predictor of the outcome of ICSI cycles. Eur J Obstet Gynecol Reprod Biol 2017 May;212:160-165.
  51. Raine-Fenning N, Jayaprakasan K, Clewes J, Joergner I, Bonaki SD, Chamberlain S, Devlin L, Priddle H, Johnson I. SonoAVC: a novel method of automatic volume calculation. Ultrasound Obstet Gynecol 2008 Jun;31(6):691-696.
  52. Zhou L, Zhang X, Chen X, Liao L, Pan R, Zhou N, Di N. Value of three-dimensional hysterosalpingo-contrast sonography with SonoVue in the assessment of tubal patency. Ultrasound Obstet Gynecol 2012 Jul;40(1):93-98.
  53. Exacoustos C, Di Giovanni A, Szabolcs B, Romeo V, Romanini ME, Luciano D, Zupi E, Arduini D. Automated three-dimensional coded contrast imaging hysterosalpingocontrast sonography: feasibility in office tubal patency testing. Ultrasound Obstet Gynecol 2013 Mar;41(3):328-335.
  54. Bonilla-Musoles F, Raga F, Osborne NG, Blanes J. Control of intrauterine device insertion with three-dimensional ultrasound: is it the future? J Clin Ultrasound 1996 Jun;24(5): 263-267.
  55. Benacerraf BR, Shipp TD, Bromley B. Three-dimensional ultrasound detection of abnormally located intrauterine contraceptive devices which are a source of pelvic pain and abnormal bleeding. Ultrasound Obstet Gynecol 2009 Jul;34(1): 110-115.
  56. Chou CY, Hsu KF, Wang ST, Huang SC, Tzeng CC, Huang KE. Accuracy of three-dimensional ultrasonography in volume estimation of cervical carcinoma. Gynecol Oncol 1997 Jul;66(1): 89-93.
  57. Alcazar JL, Jurado M. Three-dimensional ultrasound for assessing women with gynecological cancer: a systematic review. Gynecol Oncol 2011 Mar;120(3):340-346.
  58. Pascual MA, Graupera B, Hereter L, Rotili A, Rodriguez I, Alcazar JL. Intra- and interobserver variability of 2D and 3D transvaginal sonography in the diagnosis of benign versus malignant adnexal masses. J Clin Ultrasound 2011 Jul;39(6):316-321.
  59. Acharya UR, Sree SV, Krishnan MM, Saba L, Molinari F, Guerriero S, Suri JS. Ovarian tumor characterization using 3D ultrasound. Technol Cancer Res Treat 2012 Dec;11(6):543-552.
  60. Belitsos P, Papoutsis D, Rodolakis A, Mesogitis S, Antsaklis A. Three-dimensional power Doppler ultrasound for the study of cervical cancer and precancerous lesions. Ultrasound Obstet Gynecol 2012 Nov;40(5):576-581.
  61. Perez-Medina T, Orensanz I, Pereira A, Valero de Bernabé J, Engels V, Troyano J, SanFrutos L, Iglesias E. Three-dimensional angioultrasonography for the prediction of malignancy in ovarian masses. Gynecol Obstet Invest 2013;75(2):120-125.
  62. Rotten D, Levaillant JM, Zerat L. Analysis of normal breast tissue and of solid breast masse using three-dimensional ultrasound mammography. Ultrasound Obstet Gynecol 1999 Aug;14(2):114-124.
  63. Merz E, Oberstein A. 3D and 4D breast ultrasound. In: Ultrasound in obstetrics and gynecology. Vol. 2: Gynecology. New York: Thieme Stuttgart; 2007. pp. 266-296.
  64. Weismann C, Mayr C, Egger H, Auer A. Breast sonography— 2D, 3D, 4D ultrasound or elastography? Breast Care 2011;6:98-103.
  65. Vourtsis A, Kachulis A. The performance of 3D ABUS versus HHUS in the visualisation and BI-RADS characterisation of breast lesions in a large cohort of 1,886 women. Eur Radiol 2018 Feb;28(2):592-601.
  66. Meel-van den Abeelen AS, Weijers G, van Zelst JC, Thijssen JM, Mann RM, de Korte CL. 3D quantitative breast ultrasound analysis for differentiating fibroadenomas and carcinomas smaller than 1 cm. Eur J Radiol 2017 Mar;88:141-147.
  67. Weismann CF, Forstner R, Prokop E, Rettenbacher T. Threedimensional targeting: a new three-dimensional ultrasound technique to evaluate needle position during breast biopsy. Ultrasound Obstet Gynecol 2000 Sep;16(4):359-364.
  68. Delle Chiaie L, Terinde R. Three-dimensional ultrasoundvalidated large-core needle biopsy: is it a reliable method for the histological assessment of breast lesions? Ultrasound Obstet Gynecol 2004 Apr;23(4):393-397.
  69. Kurjak A. 3D/4D sonography (Editorial). J Perinat Med 2017 Aug 28;45(6):639-641.
  70. Islam MS, Protic O, Giannubilo SR, Toti P, Tranquilli AL, Petraglia F, Castellucci M, Ciarmela P. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab 2013 Mar;98(3):921-934.
  71. Ciarmela P, Ciavattini A, Giannubilo SR, Lamana P, Fiorini R, Tranquili AL, Christman GM, Castellucciu M. Management of leiomyomas in perimenopausal women. Maturitas 2014 Jul; 78(3):168-173.
  72. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest 2005;59(1):29-35.
  73. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol 1991 May;77(5):720-725.
  74. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006 Dec;108(6):1381-1387.
  75. Carbonell Esteve JL, Acosta R, Heredia B, Perez Y, Castaneda MC, Hernandez AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008 Nov;112(5):1029-1036.
  76. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012 Feb;366(5): 409-420.
  77. Ghezzi F, Cromi A, Bergamini V, Scarperi S, Bolis P, Franchi M. Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas. Surg Endosc 2007 Nov;21(11): 2081-2085.
  78. Kanaoka Y, Yoshida C, Fukuda T, Kajitani K, Ishiko O. Transcervical microwave myolysis for uterine myomas assisted by transvaginal ultrasonic guidance. J Obstet Gynaecol Res 2009 Feb;35(1):145-151.
  79. Stewart EA, Rabinovici J, Tempany CM, Inbar Y, Regan L, Gostout B, Hesley G, Kim HS, Hengst S, Gedroyc WM. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006 Jan;85(1):22-29.
  80. Taran FA, Tempany CM, Regan L, Inbar Y, Revel A, Stewart EA. Magnetic resonance-guided focused ultrasound (MRgFUS) compared with abdominal hysterectomy for treatment of uterine leiomyomas. Ultrasound Obstet Gynecol 2009 Nov;34(5):572-578.
  81. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990.1997. Obstet Gynecol 2002 Feb;99(2):229-234.
  82. Cicinelli E, Romano F, Anastasio PS, Blasi N, Parisi C, Galantino P. Transabdominal sonohysterography, transvaginal sonography, and hysteroscopy in the evaluation of submucous myomas. Obstet Gynecol 1995 Jan; 85(1):42-47.
  83. Furr BJA, Jordan VC. The pharmacology and clinical uses of Tamoxifen. Pharmacol Ther 1984;25(2):127-205.
  84. Barakat R. The effect of Tamoxifen on the endometrium. Oncology 1995 Feb;9(2):129-142.
  85. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994 Sep;47(9):827-833.
  86. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Tamoxifen and the uterus and endometrium. Lancet 1989 Feb; 1(8634):375.
  87. Kedar RP, Bourne TH, Powels TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994 May;343(8909):1318-1321.
  88. Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, Habiba M. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomized control trial. Gynecol Oncol 2009 Sep;114(3):452-456.
  89. Deligdisch L, Kalir T, Cohen CJ, de Latour M, le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000 Aug;78(2):181-186.
  90. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004 Aug;94(2):256.
  91. Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, Vogel VG, Wolmark N. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). Am J Obstet Gynecol 2011 Dec;205(6):535.e1-5.
  92. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994 Apr;86(7):527-537.
  93. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994 Feb;343(8895):448-452.
  94. Deligdisch L, Kalir N, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000 Aug;78(2):181-186.
  95. Ryden S, Fermo M, Moller T. Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol 1992;31(2):271-274.
  96. Cummings FJ, Gray R, Tormey DC, Davis TE, Volk H, Harris J, Falkson G, Bennett JM. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol 1993;11(1):29-35.
  97. Fotiou S, Hatjeleftheriou G, Kyrousis G, Kokka F, Apostolikas N. Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature. Anticancer Res 2000 May;20(3B):2015-2020.
  98. Cohen R, Perel E, Flex E, Tepper R, Altaras MM, Cordoba M, Beyth Y. Endometrial pathologies in postmenopausal tamoxifen treatment: comparison between gynaecological symptomatic and gynaecological asymptomatic breast cancer patients. J Clin Pathol 1999 Apr;52(4):278-282.
  99. Cohen R, Azaria, J. Shapira, Yigael D, Tepper R. The significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women. Cancer 2002 Jun;94(12):3101-3106.
  100. El.bieta S, Tomasz K, Jacek J. The effects of tamoxifen on the female genital tract. Cancer Treat Rev 2004 May;30(3):291-301.
  101. Tamoxifen and uterine cancer. Committee Opinion No 601. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:1394-1397.
  102. Gerber B, Krause A, Muller H, Reimer T, Külz T, Makovitzky J, Kundt G, Friese K. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000 Oct;18(20):3464-3470.
  103. Markovitch O, Tepper R, Aviram R, Fishman A, Shapira J, Cohen I. The value of sonohysterography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 2004 Sep;94(3):754-759.
  104. Berliere M, Radikov G, Galant C, Piette P, Marbaix E, Donnez J. Identification of women at high risk of developing endometrial cancer on tamoxifen. Eur J Cancer 2000 Sep;36(suppl 4): S35-S36.
  105. Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol 2002 Feb;101(1):58-63.
  106. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 2005 Apr;192(4):1230-1237.
  107. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel releasingintrauterine system for endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol 2010 Dec;203(6):547.e1-547.e10.
  108. Chan SS, Tam WH, Yeo W, Yu MMY, Ng DPS, Wong AWY, Kwan WH, Yuen PM. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 2007 Dec;114(12):1510-1515.
  109. Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, Habiba M. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel-releasing intrauterinesystem; long-term follow-up of a randomised control trial. Gynecol Oncol 2009 Sep;114(3):452-456.
  110. Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011 Mar;83(3):211-217.
  111. Stein RI, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-185.
  112. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012 Jan;97(1):28-38.e25
  113. Sirmans SM, Pate KA. Epidemiology, diagnosis and management of polycystic ovary syndrome. Clin Epidemiol 2014; 6:1-13.
  114. Fauser BC, Diedrich K, Bouchard P, Domínguez F, Matzuk M, Franks S, Hamamah S, Simón C, Devroey P, Ezcurra D, et al. Contemporary genetic technologies and female reproduction. Human Reproduction Update 2011 Nov;17(6):829-847.
  115. Balen A, Conway G, Kaltsas G. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995 Aug;10(8):2107-2111.
  116. Azziz R, Sanchez L, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004 Feb;89(2):453-462.
  117. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at longterm follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000 May;52(5):595-600.
  118. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 2007 Jun;87(6): 1369-1376.
  119. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Givens JHF, Merriman G, editors. The polycystic ovary syndrome. Cambridge, MA: Blackwell Scientific; 1992. p. 377-384.
  120. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 Jan;81(1):19-25.
  121. Azziz R, Carmina E, DeWailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006 Nov;91(11):4237-4245.
  122. Lujan ME, Jarrett BY, Brooks ED, Reines JK, Peppin AK, Muhn N, Haider E, Pierson RA, Chizen DR. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod 2013 May;28(5):1361-1368.
  123. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health 2011 Feb;3:25-35.
  124. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No 108: Polycystic ovary syndrome. Obstet Gynecol 2009 Oct;114(4):936-949.
  125. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008 Mar;89(3): 505-522.
  126. Balen AH. Ovulation induction in the management of anovulatory polycystic ovary syndrome. Mol Cell Endocrinol 2013 Jul;373(1-2):77-82.
  127. Berridge DL, Winter TC. Saline infusion sonohysterography: technique, indications, and imaging findings. J Ultrasound Med 2004 Jan;23(1):97-112.
  128. Allison SJ, Horrow MM, Kim HY, Lev-Toaff AS. Salineinfused sonohysterography: tips for achieving greater success. Radiographics 2011 Nov-Dec;31(7):1991-2004.
  129. O'Neill MJ. Sonohysterography. Radiol Clin North Am 2003 Jul;41(4):781-797.
  130. Bonnamy L, Marret H, Perrotin F, Body G, Berger C, Lansac J. Sonohysterography: a prospective survey of results and complications in 81 patients. Eur J Obstet Gynecol Reprod Biol 2002 Apr;102(1):42-47.
  131. Lindheim SR, Adsuar N, Kushner DM, Pritts EA, Olive DL. Sonohysterography: a valuable tool in evaluating the female pelvis. Obstet Gynecol Surv 2003 Nov;58(11):770-784.
  132. Lindheim SR, Sprague C, Winter TC. Hysterosalpingography and sonohysterography: lessons in technique. AJR Am J Roentgenol 2006 Jan;186(1):24-29.
  133. Jeanty P, Besnard S, Arnold A, Turner C, Crum P. Air-contrast sonohysterography as a first step assessment of tubal patency. J Ultrasound Med 2000 Aug;19(8):519-527.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.